Program purpose |
Advisory role in relation to evidence and policy |
Advisory role only in relation to evidence |
Advisory role in relation to evidence and policy |
Advisory role in relation to evidence and policy |
Governance and organization |
Government agency |
Independent, nonprofit agency |
Government agency |
Government commission |
Medical Services Advisory Committee, Protocol Advisory Sub-Committee, Evaluation Sub-committee |
Drug Policy Advisory Committee, Canadian Drug Expert Committee, COMPUS Expert Review Committee, in addition to specialist panels for specific projects |
Four technology assessment standing committees |
SE/CONITEC, Plenary, Technical Sub-Commission for the Assessment of CPTG, Technical Sub-Commission for Updating the RENAME and FTN; and Technical Sub-Commission for Updating RENASES |
Scope |
Products (including vaccines), diagnostic tests (including pathology), medical devices, surgically implanted prostheses, medical procedures and services, surgical interventions, and public health interventions. Pharmaceuticals: responsibility of the PBAC Prostheses: responsibility of the PLAC |
Pharmaceuticals, medical devices, medical procedures and health system used in health maintenance, treatment, and promotion |
Pharmaceutical products, medical devices, diagnostic techniques, surgical procedures, treatment technologies, and health promotion activities |
Pharmaceuticals, products and procedures (vaccines, in vitro diagnostic products, equipment, technical procedures, organizational, information, and educational, and support systems, care programs and protocols) |
Key factors analyzed |
Safety, clinical effectiveness, and cost-effectiveness |
Efficacy, effectiveness, cost-effectiveness, and impact on service |
Clinical effectiveness and cost-effectiveness |
Efficacy, accuracy, effectiveness, safety, cost-effectiveness, and budgetary impact |
Stakeholder involvement |
The MSAC sub-committees include clinical specialists and consumer representatives. Topic definition and selection: open to all applicants for public funding Research protocol: work with applicant/industry and input from the public Evidence review: applicants can give their opinion MSAC pre-assessment report: applicants can give their opinion (public consultation) |
Topic definition: open to the public, topics refined with the proponent Evidence review: information requested from manufacturers, authors of reports, and other specialist Implementation: Knowledge Transfer Program centered on relaying the research to decision makers |
Stakeholders are involved in every stage of the HTA process Consultants invited to present statements and participate in the HTA process (including, for example, national patient groups, industry, health professionals, and Department of Health) Commentator organizations are also invited to participate in the HTA process |
Topic definition: not restrictions on the type of applicant Plenary of CONITEC includes representatives of the CFM, CNS, CONASS, CONASEMS, ANS, ANVISA, as well as the Ministry of Health CONITEC may invite external specialists to assist, collaborate in meetings, or provide technical inputs and/or sign technical cooperation agreements Stakeholders can provide input during the public consultation process and/or public hearing Applicants may appeal against decisions/recommendations published in the official gazette |
Target audience |
Australia’s Department of Health and Aging, health professionals, hospitals, and consumers |
Territorial, provincial, and federal health ministries, including drug plans, regional health authorities, and hospitals and clinics |
NHS, doctors, patients and carers (England and Wales) |
SUS, health professionals, and industry |